Equities Analysts Issue Forecasts for CMPX FY2024 Earnings

Compass Therapeutics, Inc. (NASDAQ:CMPX) – HC Wainwright raised their FY2024 EPS estimates for shares of Compass Therapeutics in a research report issued on Tuesday, November 12th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings of ($0.36) per share for the year, up from their previous estimate of ($0.42). HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Compass Therapeutics’ current full-year earnings is ($0.42) per share. HC Wainwright also issued estimates for Compass Therapeutics’ Q4 2024 earnings at ($0.11) EPS, FY2025 earnings at ($0.33) EPS, FY2026 earnings at ($0.29) EPS and FY2027 earnings at $0.09 EPS.

Compass Therapeutics (NASDAQ:CMPX) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.03.

A number of other research firms also recently issued reports on CMPX. Wedbush restated an “outperform” rating and set a $8.00 price target on shares of Compass Therapeutics in a research note on Wednesday, August 7th. Leerink Partners lowered shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $5.00 to $4.00 in a research report on Friday. Leerink Partnrs downgraded shares of Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday. Finally, LADENBURG THALM/SH SH upgraded shares of Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 price target for the company in a research note on Monday, September 16th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Compass Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $6.75.

Compass Therapeutics Stock Performance

CMPX opened at $1.38 on Friday. Compass Therapeutics has a one year low of $0.77 and a one year high of $2.34. The stock has a market capitalization of $189.87 million, a P/E ratio of -3.73 and a beta of 0.92. The business’s 50-day simple moving average is $1.75 and its 200-day simple moving average is $1.42.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Rovin Capital UT ADV purchased a new stake in shares of Compass Therapeutics during the third quarter worth approximately $25,000. Intech Investment Management LLC acquired a new position in Compass Therapeutics in the 3rd quarter valued at $30,000. XTX Topco Ltd purchased a new position in Compass Therapeutics during the 3rd quarter worth $37,000. Cubist Systematic Strategies LLC purchased a new position in Compass Therapeutics during the 2nd quarter worth $41,000. Finally, Panagora Asset Management Inc. acquired a new stake in shares of Compass Therapeutics in the 2nd quarter worth $68,000. 68.43% of the stock is currently owned by hedge funds and other institutional investors.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.